Trial Profile
Phase 3 study of K-828-SP (Long-term study of sodium valproate in child patients with spinal muscular atrophy)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Sodium valproate (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kowa Pharmaceutical
- 08 Nov 2018 Status changed from active, no longer recruiting to completed.
- 27 Sep 2017 Planned End Date changed from 31 Mar 2018 to 30 Sep 2018.
- 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.